Daveen Chopra, Corporate Vice President of Transcatheter Mitral and Tricuspid Therapies (TMTT) at Edwards Lifesciences Corp (NYSE:EW), a $42.4 billion medical devices company with strong financial health according to InvestingPro analysis, recently sold 1,750 shares of the company's common stock. The transaction, executed on December 6, 2024, was conducted at an average price of $73.27 per share, amounting to a total value of $128,222. Following this sale, Chopra retains ownership of 27,583 shares. This transaction was part of routine changes in beneficial ownership and does not reflect other securities held by Chopra. The company maintains robust financials with a current ratio of 3.46 and more cash than debt on its balance sheet. InvestingPro subscribers can access detailed insider trading patterns and 8 additional key insights about Edwards Lifesciences, including comprehensive Fair Value analysis and management's aggressive share buyback activity.
In other recent news, Edwards Lifesciences, a key player in the medical technology industry, has been in the spotlight due to several significant developments. TD (TSX:TD) Cowen maintained a Hold rating on the company's stock after Edwards Lifesciences presented a promising multiyear outlook at its annual investor day. This included a reiteration of its 2024 guidance and the introduction of its 2025 projections, which align with current market estimates.
Bernstein SocGen Group also maintained its Market Perform rating on Edwards Lifesciences, acknowledging the company's balanced guidance for the upcoming years. The company's Transcatheter Aortic Valve Replacement (TAVR) growth forecast was set at 5%-7% for 2025, indicating a conservative yet optimistic growth outlook for the medium to long term.
RBC (TSX:RY) Capital Markets held an Outperform rating on Edwards Lifesciences, while Truist Securities and Canaccord Genuity (TSX:CF) both maintained a Hold rating on the stock. The companies increased their price targets following Edwards Lifesciences' investor day, which highlighted strategies for revenue and earnings growth. The company's Transcatheter Mitral and Tricuspid Therapies (TMTT) segment projections for 2025 and the long term were above consensus, driven by the momentum of the Evoque product and the upcoming mitral replacement (M3) system.
These recent developments underscore the company's strong financial performance and potential for future growth. However, the Hold ratings suggest that investors should maintain their current positions in the stock until further developments potentially alter the investment outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.